Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 4
2011 2
2012 6
2013 17
2014 25
2015 17
2016 22
2017 23
2018 18
2019 7
2020 8
2021 8
2022 1
2023 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30061269

130 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR, Bathala T, Campbell MT, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Matrana MR, et al. BJU Int. 2016 Aug;118(2):264-71. doi: 10.1111/bju.13374. Epub 2015 Dec 13. BJU Int. 2016. PMID: 26573089 Free PMC article.
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID. Sternberg CN, et al. Eur J Cancer. 2013 Apr;49(6):1287-96. doi: 10.1016/j.ejca.2012.12.010. Epub 2013 Jan 12. Eur J Cancer. 2013. PMID: 23321547 Clinical Trial.
130 results